KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading →
Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading →
The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading →
2000 May 20, 2000 – WHO passes WHA 53.17, which calls for research, prevention, collaboration, and capacity building to prevent and control noncommunicable diseases 2002 April 13, 2002 –The Salt Institute and other industry lobbying groups release their first comments… Continue Reading →
On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading →
Blogs about compulsory licensing in Colombia are here.
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading →
Gilead 10-Q, 3rd quarter 2017 If any party is successful in establishing exclusive rights to axi-cel, our anticipated revenues and earnings from the sale of that product could be adversely affected. In October 2017, we acquired Kite, which is now… Continue Reading →
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading →